Wei Li
Impact in
- Cancer Research top 0.1%
- Cancer, Hypoxia, and Metabolism
- Oncology top 0.1%
- HER2/EGFR in Cancer Research
Papers in
- Oncology 258
- HER2/EGFR in Cancer Research 47
- Cancer-related Molecular Pathways 41
-
- Cancer therapeutics and mechanisms 55
- Co-authors
- Duane D. Miller (97 shared papers)Andrzej T. Slominski (68 shared papers)Robert Charles Tuckey (54 shared papers)Chunlei Liu (14 shared papers)Tae‐Kang Kim (39 shared papers)Jianjun Chen (19 shared papers)Bing Heng Wu (5 shared papers)Yan Lü (20 shared papers)
- Journals
- Journal of Medicinal Chemistry (27 papers)PLoS ONE (20 papers)Journal of Biological Chemistry (18 papers)Frontiers in Oncology (18 papers)Scientific Reports (17 papers)
- Partner nations
- ChinaUnited StatesAustralia
In The Last Decade
Wei Li
1.4k papers receiving 58.1k citations
Wei Li's Hit Papers
Peers
Comparison fields: 5 of 213
- Cancer Research 6.8k
- Oncology 11.9k
- Pathology and Forensic Medicine 4.7k
- Molecular Biology 18.9k
- Pulmonary and Respiratory Medicine 7.5k
Countries citing papers authored by Wei Li
This map shows the geographic impact of Wei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Li more than expected).
Fields of papers citing papers by Wei Li
This network shows the impact of papers produced by Wei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Li. The network helps show where Wei Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 1.4k papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation Hit paper breakdown → | 2017 | 2560 |
| 2 | The ATLAS Experiment at the CERN Large Hadron Collider Hit paper breakdown → | 2008 | 2154 |
| 3 | Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Hit paper breakdown → | 2022 | 1875 |
| 4 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Hit paper breakdown → | 2014 | 1736 |
| 5 | HIF-1α pathway: role, regulation and intervention for cancer therapy Hit paper breakdown → | 2015 | 1564 |
| 6 | Measurements of the Higgs boson production and decay rates and constraints on its couplings from a combined ATLAS and CMS analysis of the LHC pp collision data at s = 7 $$ \sqrt{s}=7 $$ and 8 TeV Hit paper breakdown → | 2016 | 808 |
| 7 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 699 |
| 8 | An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site Hit paper breakdown → | 2012 | 661 |
| 9 | Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition Hit paper breakdown → | 2011 | 544 |
| 10 | Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial Hit paper breakdown → | 2022 | 472 |
| 11 | Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study Hit paper breakdown → | 2017 | 424 |
| 12 | 2011 | 409 | |
| 13 | 2015 | 403 | |
| 14 | 2009 | 387 | |
| 15 | Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors Hit paper breakdown → | 2016 | 375 |
| 16 | The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients Hit paper breakdown → | 2016 | 374 |
| 17 | Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial Hit paper breakdown → | 2015 | 364 |
| 18 | 2017 | 350 | |
| 19 | 2009 | 347 | |
| 20 | Steroidogenesis in the skin: Implications for local immune functions Hit paper breakdown → | 2013 | 321 |
About Wei Li
Wei Li is a scholar working on Oncology, Molecular Biology, Cancer Research, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 1.4k papers that have together received 59.5k indexed citations. Recurring topics across this work include Synthesis and biological activity (61 papers), Lung Cancer Treatments and Mutations (59 papers), Cancer therapeutics and mechanisms (55 papers), Vitamin D Research Studies (53 papers), Estrogen and related hormone effects (49 papers), HER2/EGFR in Cancer Research (47 papers), Click Chemistry and Applications (43 papers) and Cancer-related Molecular Pathways (41 papers). The work is most often cited by research in Cancer Research (6.8k citations), Oncology (11.9k citations), Pathology and Forensic Medicine (4.7k citations), Molecular Biology (18.9k citations) and Pulmonary and Respiratory Medicine (7.5k citations). Wei Li has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Duane D. Miller, Andrzej T. Slominski, Robert Charles Tuckey, Chunlei Liu, Tae‐Kang Kim, Jianjun Chen, Bing Heng Wu, Yan Lü, Zorica Janjetović and Jin Wang. Their work appears in journals such as Journal of Medicinal Chemistry, PLoS ONE, Journal of Biological Chemistry, Frontiers in Oncology and Scientific Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.